Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapies to treat cardiovascular diseases caused by specific genetic mutations, including Friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and hypertrophic cardiomyopathy. The company's proprietary AAVrh10 vector platform is designed to deliver therapeutic genes directly to heart muscle tissue with high efficiency and favorable biodistribution characteristics. Lexeo advances a portfolio of candidates targeting rare and prevalent cardiovascular genetic indications with significant unmet medical need, retaining exclusive worldwide development and commercialization rights, and generating value through eventual licensing, clinical milestone achievements, and potential product approvals and commercialization.